Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile ATM loss
Therapy Niraparib
Indication/Tumor Type pancreatic ductal adenocarcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ATM loss pancreatic ductal adenocarcinoma predicted - sensitive Niraparib Case Reports/Case Series Actionable In a Phase II trial, Zejula (niraparib) treatment in metastatic pancreatic ductal adenocarcinoma patients harboring mutations in ATM (n=14), BRCA1 (n=2), BRCA2 (n=10), CHEK2 (n=4), or PALB2 (n=3) resulted in a 6-month progression-free survival rate of 25%, objective response rate of 14% (4/32, 2 complete, 2 partial responses), and median overall survival of 10.2 mo in the overall cohort, and prolonged response greater than 1 year in 3 patients with biallelic ATM loss (PMID: 41686836; NCT03601923). 41686836
PubMed Id Reference Title Details
(41686836) A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Full reference...